NCT07035288View on ClinicalTrials.gov

PulseSelect Based Pulmonary Vein Isolation and Ablation in Patients With Atrial Fibrillation

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

July 10, 2025

Conditions
Atrial Fibrillation (AF)Catheter AblationPulmonary Vein Isolation
Interventions
DEVICE

EAM based Pulmonary Vein Isolation

"20 patients with symptomatic paroxysmal or persistent AF will be scheduled for pulmonary vein isolation (PVI) based to EAM by means of the PulseSelect catheter.~Ablation will be performed in a deep sedation setting and additional ablation within the pulmonary veins will be assessed"

DEVICE

Fluoro based pulmonary vein ablation

"20 patients with symptomatic paroxysmal or persistent AF will be scheduled for pulmonary vein isolation (PVI) based to Fluoroscopy by means of the PulseSelect catheter.~Ablation will be performed in a deep sedation setting and additional ablation within the pulmonary veins will be assessed"

Trial Locations (1)

11527

First Department of Cardiology, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens

All Listed Sponsors
collaborator

Medtronic Atrial Fibrillation Solutions

INDUSTRY

lead

Tsiachris Dimitrios

OTHER

NCT07035288 - PulseSelect Based Pulmonary Vein Isolation and Ablation in Patients With Atrial Fibrillation | Biotech Hunter | Biotech Hunter